Skip to content
ppharmaranks
Menu

Best treatments for lymphoid leukemia

12 products may treat lymphoid leukemia, spanning FDA drug classes such as kinase inhibitor, alkylating drug, cd20-directed cytolytic antibody. The current highest-rated option is blincyto. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.

Quick answer: Of the 12 drugs we list for lymphoid leukemia, 4 are available as lower-cost generics, spanning classes such as kinase inhibitor, alkylating drug, cd20-directed cytolytic antibody. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for lymphoid leukemia — so confirm the right choice with your prescriber.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Top-rated picks for lymphoid leukemia: 1. Blincyto · 2. Riabni · 3. Sprycel

Top-rated treatments for lymphoid leukemia, ranked by pharmaranks score
#DrugRatingPharmacy pays
172/100View →
272/100View →
372/100$839View →
472/100View →
570/100View →
670/100$26View →
770/100View →
870/100View →
970/100View →
10Not yet rated$26View →

Full ranking · 12 treatments

blincyto

Boxed warning

PrescriptionFDA-sourced

72/100

Blincyto (Blinatumomab) is a medication used to treat Lymphoid Leukemia.

(6 data points)
leukemia, lymphoid

Price varies

View details →

riabni

Boxed warning

PrescriptionFDA-sourced

72/100

Riabni (Rituximab-Arrx) is a medication used to treat Rheumatoid Arthritis, Lymphoid Leukemia, Granulomatosis with Polyangiitis, B-Cell Lymphoma.

(6 data points)
arthritis, rheumatoidleukemia, lymphoidgranulomatosis with polyangiitis

Price varies

View details →
BRISTOL MYERS SQUIBB logo
#1 of 20 in Kinase Inhibitor

sprycel

PrescriptionFDA-sourced

72/100

Sprycel (Dasatinib) is a kinase inhibitor used to treat Lymphoid Leukemia, Myeloid Leukemia.

(4 data points)
kinase inhibitorleukemia, lymphoidleukemia, myeloid

Pharmacy pays

~$839.19 /30

Save up to 97% in class
View details →
ABBVIE logo

venclexta

PrescriptionFDA-sourced

72/100

Venclexta (Venetoclax) is a medication used to treat Lymphoid Leukemia.

(6 data points)
leukemia, lymphoid

Price varies

View details →
#2 of 11 in Alkylating Drug

bendeka

PrescriptionFDA-sourced

70/100

Bendeka (Bendamustine Hydrochloride) is an alkylating drug used to treat Lymphoid Leukemia, Non-Hodgkin Lymphoma.

(1 data points)
alkylating drugleukemia, lymphoidlymphoma, non-hodgkin

Price varies

View details →
NOVARTIS logo
#3 of 20 in Kinase Inhibitor

gleevec

PrescriptionFDA-sourced

70/100

Gleevec (Imatinib Mesylate) is a kinase inhibitor used to treat Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome, Dermatofibrosarcoma.

(13 data points)
kinase inhibitorleukemia, lymphoidleukemia, myeloid

Pharmacy pays

From ~$23.82/30· 2 forms
View details →

Frequently asked

What treats lymphoid leukemia?
Our catalog lists 12 products that may treat lymphoid leukemia, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is blincyto.
What is the best-rated treatment for lymphoid leukemia?
By our independent recall-safety rating — not an efficacy measure — blincyto ranks highest among the products we list for lymphoid leukemia. Always consult a professional.
How are these treatments ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
What types of drugs treat lymphoid leukemia?
Treatments for lymphoid leukemia span FDA drug classes including kinase inhibitor, alkylating drug, cd20-directed cytolytic antibody. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.